Literature DB >> 18977852

Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications.

M Pisano, P Baldinu, M C Sini, P A Ascierto, F Tanda, G Palmieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18977852      PMCID： PMC2733126          DOI： 10.1093/annonc/mdn672

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Chemosensitisation of malignant melanoma by BCL2 antisense therapy.

Authors:  B Jansen; V Wacheck; E Heere-Ress; H Schlagbauer-Wadl; C Hoeller; T Lucas; M Hoermann; U Hollenstein; K Wolff; H Pehamberger
Journal:  Lancet       Date:  2000-11-18       Impact factor: 79.321

Review 2.  Multitarget tyrosine kinase inhibition: [and the winner is...].

Authors:  Jaap Verweij; Maja de Jonge
Journal:  J Clin Oncol       Date:  2007-06-10       Impact factor: 44.544

3.  Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.

Authors:  Luba Benimetskaya; Kanyalakshmi Ayyanar; Noah Kornblum; Daniela Castanotto; John Rossi; Sijian Wu; Johnathan Lai; Bob D Brown; Natalia Popova; Paul Miller; Harilyn McMicken; Yin Chen; C A Stein
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

4.  Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

Authors:  Agop Y Bedikian; Michael Millward; Hubert Pehamberger; Robert Conry; Martin Gore; Uwe Trefzer; Anna C Pavlick; Ronald DeConti; Evan M Hersh; Peter Hersey; John M Kirkwood; Frank G Haluska
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

Review 5.  Molecular targets in melanoma from angiogenesis to apoptosis.

Authors:  Jeffrey A Sosman; Igor Puzanov
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531
  5 in total
  2 in total

Review 1.  Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma.

Authors:  S Wu; R K Singh
Journal:  Curr Mol Med       Date:  2011-10       Impact factor: 2.222

Review 2.  Noncoding RNA therapeutics - challenges and potential solutions.

Authors:  Melanie Winkle; Sherien M El-Daly; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2021-06-18       Impact factor: 84.694
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.